We are live on !
Find out more
KCM
Kynam Capital Management Portfolio holdings
AUM
$1.81B
Turnover
34.88%
1-Year Est. Return
192.15%
This Fund
S&P 500
This Quarter Est. Return
+24.45%
1 Year Est. Return
+192.15%
3 Year Est. Return
+320.12%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.81B
AUM Growth
+$188M
(+12%)
Cap. Flow
+$7.54M
Cap. Flow % of AUM
Cap. Flow %
0.42%
Top 10 Holdings %
Top 10 Hldgs %
72.72%
Holding
43
New
4
Increased
12
Reduced
7
Closed
11
Avg Time Held
Equity + Options
2.1
years
Top 10 Avg Time Held
Equity + Options
2
years
Top 20 Avg Time Held
Equity + Options
1.6
years
Avg Time Held Equity only
2.1
years
Top 10 Avg Time Held Equity only
2.4
years
Top 20 Avg Time Held Equity only
1.6
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Viridian Therapeutics
VRDN
|
+$66.3M |
| 2 |
Legend Biotech
LEGN
|
+$38.4M |
| 3 |
Relay Therapeutics
RLAY
|
+$27.2M |
| 4 |
CytomX Therapeutics
CTMX
|
+$25.5M |
| 5 |
Summit Therapeutics
SMMT
|
+$21.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
KalVista Pharmaceuticals
KALV
|
+$36.7M |
| 2 |
Apellis Pharmaceuticals
APLS
|
+$33.2M |
| 3 |
BioCryst Pharmaceuticals
BCRX
|
+$28.6M |
| 4 |
Beam Therapeutics
BEAM
|
+$25.4M |
| 5 |
Vera Therapeutics
VERA
|
+$18.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
Celldex Therapeutics
CLDX
$2.28B
| $198M | 10.95% |
5,322,908
-517,659
| -9% | -$16.7M |
2021 Q4
18 quarters
|
|
2
Syndax Pharmaceuticals
SNDX
$1.21B
| $176M | 9.73% |
8,050,959
| – | – |
2021 Q4
18 quarters
|
|
3
Vaxcyte
PCVX
$9.9B
| $170M | 9.39% |
2,922,335
| – | – |
2021 Q4
18 quarters
|
|
4
Cogent Biosciences
COGT
$5.43B
| $142M | 7.84% |
3,667,097
-370,234
| -9% | -$13M |
2022 Q2
16 quarters
|
|
|
5
Vera Therapeutics
VERA
$2.09B
| $124M | 6.85% |
2,890,059
-508,165
| -15% | -$18.9M |
2021 Q4
18 quarters
|
|
|
6
Viridian Therapeutics
VRDN
$2.59B
| $119M | 6.55% |
6,453,877
+4,112,225
| +176% | +$66.3M |
2021 Q4
18 quarters
|
|
7
Travere Therapeutics
TVTX
$4.94B
| $114M | 6.28% |
2,000,000
+430,982
| +27% | +$19.1M |
2021 Q4
18 quarters
|
|
|
8
Beam Therapeutics
BEAM
$2.54B
| $97.5M | 5.39% |
2,840,792
-841,393
| -23% | -$25.4M |
2024 Q3
7 quarters
|
|
9
UroGen Pharma
URGN
$1.72B
| $89.6M | 4.95% |
2,434,207
+186,814
| +8% | +$5.06M |
2026 Q1
1 quarter
|
|
|
10
Legend Biotech
LEGN
$3.68B
| $86.7M | 4.79% |
3,001,205
+1,424,910
| +90% | +$38.4M |
2026 Q1
1 quarter
|
|
|
11
CytomX Therapeutics
CTMX
$532M
| $81.4M | 4.5% |
21,703,093
+6,690,000
| +45% | +$25.5M |
2025 Q2
4 quarters
|
|
|
12
Relay Therapeutics
RLAY
$4.02B
| $61.7M | 3.41% |
3,300,000
+1,875,741
| +132% | +$27.2M |
2024 Q4
6 quarters
|
|
13
Cullinan Oncology
CGEM
$960M
| $56.7M | 3.13% |
3,114,132
| – | – |
2024 Q4
6 quarters
|
|
14
MBX Biosciences
MBX
$2.43B
| $51.6M | 2.85% |
934,799
| – | – |
2025 Q3
3 quarters
|
|
15
Immunocore
IMCR
$1.65B
| $43.7M | 2.41% |
1,375,000
+490,063
| +55% | +$14.5M |
2024 Q4
6 quarters
|
|
16
Nurix Therapeutics
NRIX
$2.79B
| $29M | 1.6% |
1,194,757
| – | – |
2025 Q1
5 quarters
|
|
17
Sutro Biopharma
STRO
$171M
| $29M | 1.6% |
872,558
| – | – |
2022 Q4
14 quarters
|
|
|
18
BioCryst Pharmaceuticals
BCRX
$1.99B
| $25.2M | 1.39% |
2,522,660
-3,158,135
| -56% | -$28.6M |
2023 Q1
13 quarters
|
|
19
Pharvaris
PHVS
$2.15B
| $22.9M | 1.26% |
661,795
+21,400
| +3% | +$647K |
2025 Q3
3 quarters
|
|
|
20
Summit Therapeutics
SMMT
$12.4B
| $17.5M | 0.97% |
+1,200,000
| New | +$21.3M |
2026 Q2
0 quarters
|
|
21
Prelude Therapeutics
PRLD
$287M
| $12.9M | 0.71% |
2,415,087
+822,536
| +52% | +$3.58M |
2025 Q4
2 quarters
|
|
22
Insmed
INSM
$20.8B
| $10.7M | 0.59% |
+100,000
| New | +$12.1M |
2026 Q2
0 quarters
|
|
23
Burning Rock Biotech
BNR
$140M
| $10.5M | 0.58% |
1,238,563
+11,008
| +0.9% | +$156K |
2021 Q4
18 quarters
|
|
24
Geron
GERN
$726M
| $8.75M | 0.48% |
6,836,318
| – | – |
2025 Q1
5 quarters
|
|
25
Amarin Corp
AMRN
$245M
| $8.5M | 0.47% |
532,982
+60,600
| +13% | +$895K |
2021 Q4
18 quarters
|
|
Similar funds
Kynam Capital Management's Q2 2026 Portfolio in Review
As of Q2 2026, Kynam Capital Management held 43 positions worth $1.81B, up 12% from $1.62B the previous quarter. Its ten largest holdings account for 73% of the portfolio.
Kynam Capital Management's Q2 2026 filing shows 4 new, 12 increased, 7 reduced and 11 closed positions. Its largest new stake was Summit Therapeutics: 1,200,000 shares worth $17.5M. The largest sale was KalVista Pharmaceuticals, an estimated $36.7M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 97% a quarter earlier.
- Kynam Capital Management's largest Q2 2026 buy was Summit Therapeutics: 1,200,000 shares worth $17.5M.
- Kynam Capital Management added most to Viridian Therapeutics in Q2 2026, an estimated $66.3M increase.
- Kynam Capital Management's biggest Q2 2026 reduction was BioCryst Pharmaceuticals, cutting an estimated $28.6M.
- Kynam Capital Management fully exited KalVista Pharmaceuticals in Q2 2026, selling an estimated $36.7M.
- Kynam Capital Management's ten largest holdings make up 73% of its $1.81B portfolio in Q2 2026.
- Kynam Capital Management opened 4 new positions and closed 11 in Q2 2026.
- Kynam Capital Management's portfolio value rose 12% quarter-over-quarter to $1.81B.
Based on Kynam Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.